Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2022
2021
2020
Profitability Metrics
Gross Margin
25.38%
Operating Margin
92.37%
Net Margin
92.05%
Efficiency Metrics
Revenue per Expense Ratio
1.00
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
92.37%
Income Tax Rate
0.00%
EPS
1.0100000000
Balance Sheet Analysis
Current Ratio
0.00
Cash Ratio
7.25
Working Capital
$-3.63M
Debt to Equity
0.00
Debt to Assets
0.00%
Equity Ratio
98.93%
Cash Flow Analysis
Operating Cash Flow Ratio
83.27%
Free Cash Flow Ratio
83.27%
CapEx to Revenue
0.00%
Dividends Paid
$33.37M
Stock Buybacks
No buybacks
Total Shareholder Returns
$33.37M
Cash Position Change
143.54%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Detailed Growth Metrics
Core Performance
Revenue
326.45%
Net Income
395.62%
EPS
304.00%
Operating Income
397.33%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
66.32%
Operating Cash Flow
411.93%
Free Cash Flow
411.93%
Balance Sheet Health
Assets
-1.04%
Debt
0.00%
Book Value per Share
-1.59%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
-12.70%
Shares Outstanding
0.00%
Long Term Trends
3Y Revenue/Share
-45.51%
5Y Revenue/Share
-3.96%
3Y Dividend/Share
-25.40%
5Y Dividend/Share
-25.99%